Gelonghui March 12 丨 Some investors asked Dongxing Healthcare (301290.SZ) on the investor interactive platform, “Does the company have related business in the US? Are there plans to launch and develop Ar-related products?” The company replied that many of the company's products have been certified by the US FDA, Brazil's ANVISA, and South Korea's KFDA according to the different medical device regulatory policies or practices of different overseas countries or regions. The company's target overseas markets are mainly concentrated in the three major regions of South America, the Middle East and Europe. The company will strive to expand overseas markets and increase its market share.